Corporate Magazine 2012 - Boehringer Ingelheim

Companion animals – small animalsThe main small animal products address major chronicdiseases: heart failure and osteoarthritis.As the first of a new class of heart treatments termed inodilators,vetmedin® has been shown to significantlyimprove clinical signs and extend life expectancy indogs with congestive heart failure originating from dilatedcardiomyopathy or valvular insufficiency (mitraland/or tricuspid regurgitation). vetmedin® worksthrough two complementary modes of action: it opensup the blood vessels taking blood to and away from theheart, thereby lowering the pressure on the heart andreducing the work the heart has to do to pump bloodaround the dog’s body. At the same time, vetmedin® hasa direct effect on the heart muscle, helping it to beatstronger and pump blood more efficiently.prozinc® is an aqueous protamine zinc (PZI) suspensionof recombinant human insulin that is used to reducehyperglycaemia in cats with diabetes mellitus.The duramune® and fel-o-vax® brands are vaccinesdesigned to aid in the prevention of a wide spectrum ofinfectious diseases in dogs and cats. These common diseasescan be very serious and, in some cases, even fatal.Effective prevention, including appropriate vaccination,reduces the impact of these diseases on dogs and cats.metacam® is a non-steroidal anti-inflammatory drug(NSAID). It is available as an oral suspension, tabletsand injectable solution for dogs and as an oral suspensionand injectable solution for cats. In dogs, the indicationsinclude the alleviation of inflammation and painin both acute and chronic musculo-skeletal disorders, aswell as the reduction of post-operative pain followingsurgery. In cats, the indications include the alleviationof inflammation and pain in acute and chronic musculo-skeletaldisorders, as well as for alleviation of mild tomoderate post-operative pain following surgical procedures.The variety of formulations offers veterinariansand owners the flexibility to use the formulations theyprefer to manage the various levels of inflammation andpain associated with the licensed indications.94Boehringer Ingelheim annual report 2012